Review Article
Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment
Table 1
Small molecule/biological therapeutics targeting the Wnt pathway.
| | Molecule | Function | Phase/clinical trials | Cancer type | NCT Number |
| | PRI-724 | Dishevelled inhibitor | Phase 1/2 | Pancreatic cancer, acute myeloid leukemia, and colon cancer | NCT02413853
NCT01606579
NCT01764477 |
| | LGK974 | Porcupine inhibitor | Phase 1 | Melanoma, breast cancer, and pancreatic adenocarcinoma | NCT01351103 |
| | Vantictumab (OMP18R5) | Anti-Frizzled 7 receptor | Phase 1b | HER2 negative breast cancer and pancreatic cancer | NCT01345201 |
| | Ipafricept (OMP-54F28) | Fc-Frizzled 8 receptor | Phase 1a/1b | Pancreatic cancer and ovarian cancer | NCT02092363
NCT02050178 |
|
|
The clinical trial information was accessed via https://clinicaltrials.gov with National Clinical TrialNumber (NCT Number).
|
